Update on Janus kinase antagonists in inflammatory bowel disease

Abstract

Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease. These molecules are designed to selectively target the activity of specific JAKs and to offer a targeted mechanism of action without risk of immunogenicity. Based on data from clinical trials in rheumatoid arthritis and phase 2 studies in inflammatory bowel disease, tofacitinib and other JAK inhibitors are likely to become a new form of medical therapy for the treatment of inflammatory bowel disease.

Keywords: Crohn disease; Inflammatory bowel disease; Janus kinase inhibitors; Small-molecule therapy; Tofacitinib; Ulcerative colitis.